Skip to content

Maintaining Mechanical Ventilation During Cardiopulmonary Bypass for Cardiac Surgery

Beneficial Effects on Maintaining Mechanical Ventilation During Cardiopulmonary Bypass for Cardiac Surgery on Postoperative Infections

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03372174
Acronym
VECAR
Enrollment
1401
Registered
2017-12-13
Start date
2018-01-10
Completion date
2021-07-30
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiopulmonary Bypass

Keywords

cardiac surgery, mechanical ventilation, postoperative infections

Brief summary

The main objective of this study is to measure the incidence of postoperative infections in 2 groups of patients: one group of patients ventilated and one group of patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery, and demonstrate that the incidence of postoperative infections is significantly lower in patients ventilated during cardiopulmonary bypass.

Detailed description

Cardiopulmonary bypass (CBP) during cardiac surgery induces a systemic inflammatory response associated with an immune dysregulation and a significant pulmonary dysfunction. First, the inflammatory response, usually attributed to surgical trauma, contact of blood with artificial surfaces, and ischemia reperfusion injury, is responsible for a postoperative immunodepression. For instance, an early impairment of lung cellular immune response after CPB, which could promote the development of postoperative pneumonia, has been found. Along these lines, a downregulation of human leukocyte antigen-DR antigen (HLA-DR) expression on monocytes and an increase in plasma interleukin 10 (IL-10) associated with the occurrence of nosocomial infections have been reported. Second, CPB induces a pulmonary dysfunction, which ranges from a temporary and clinically insignificant reduction in arterial oxygenation to a life-threatening injury manifested as acute respiratory distress syndrome (ARDS). This phenomenon is of multifactorial sources, but one of the main mechanisms is the occurrence of atelectasis during surgery. Atelectasis has been associated with lung injury and release of cytokines by shear forces on alveoli and small airways. However, it is not clear whether this injury is due to a recruitment/derecruitment phenomenon (i.e., atelectrauma) or whether it might by itself lead to the release of cytokine. Since CPB mechanically circulates and oxygenates blood bypassing the heart and lungs, usual procedure during CPB is to stop mechanical ventilation (MV) (apnea). Nevertheless, maintaining MV with positive expiratory pressure (PEEP) during CPB diminished the occurrence of atelectasis and the postoperative inflammatory response. Thus, we investigated the effects of maintaining MV during CPB for cardiac surgery on postoperative immunodepression and found that maintaining MV during CPB decreased postoperative immune dysfunction and could be an interesting strategy to diminish the occurrence of postoperative infection (nosocomial infection) without hampering the surgical procedure. However, these findings have to be confirmed in a clinical trial using the incidence of nosocomial infection as an endpoint.

Interventions

DEVICEMaintaining mechanical ventilation during surgery

dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure

DEVICEAbsence of mechanical ventilation during surgery

absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old; * Scheduled for any cardiac surgery (elective surgery) with cardio-pulmonary bypass, aortic clamp and cardioplegia, with median sternotomy and bi-pulmonary ventilation (cardiac valvular surgery (valve replacement or repair), coronary artery surgery, ascending aortic surgery and/or combined); * Written informed consent.

Exclusion criteria

* Emergency surgery ; * Planned thoracotomy with one lung ventilation ; * Patients with known respiratory diseases (current respiratory infections, asthma, chronic obstructive or restrictive pulmonary disease, obstructive apnea syndrome) ; * Patients already intubated in the peri-operative period ; * Immunodepression defined by proven humoral or cellular deficiency, by continuous administration of steroids at any dose for more than one month prior to hospitalization, high-dose steroids (\> 15 mg / kg / day of methylprednisolone or Equivalent), radiotherapy or chemotherapy in the previous year;; * Need for vasopressor or inotropic agents before surgery ; * Any acute infection in the last month before surgery ; * Hematological disorder, autoimmune disease, immunodeficiency, immunosuppressive therapy ; * Heart failure with an left ventricular ejection fraction\<35% ; * Protected person (adults legally protected (under judicial protection, guardianship, or supervision), person deprived of their liberty.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative infectionsDuring 28 days

Secondary

MeasureTime frame
Proportion of myeloid-derived suppressor cells (MDSCs)At day 0, day 1 and day 7
Plasmatic concentration of interleukin 6 (IL-6)At day 0, day 1 and day 7
Quantity of extracellular vesicles (EV)At day 0 and day 1
Occurrence of lymphopeniaAt day 0, day 1 and day 7
Duration of antibiotic treatmentDuring 28 days
Indoleamine 2,3-Dioxygenase (IDO) activityAt day 0, day 1 and day 7
Plasmatic concentration of interleukin 10 (IL10)At day 0, day 1 and day 7
MortalityDuring 28 days
Length of hospital stayDuring 28 days
PaO2/FiO2 ratioAt day 0 and day 1
Duration of mechanical ventilationDuring 28 days
Expression of human leukocyte antigen-DR antigen (HLA-DR)At day 0, day 1 and day 7

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026